secwatch.observer — SEC 8-K summary
======================================

Issuer:     CYPHERPUNK TECHNOLOGIES INC. (CYPH)
CIK:        0001509745
Form:       8-K
Filed at:   2024-01-16T23:59:59+00:00
Accession:  0001104659-24-004162
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Leap Therapeutics reports 30% ORR and 93% DCR in Part A of DeFianCe study for DKN-01 in second-line CRC
--------------------------------------------------------------------------------

- Across 27 evaluable microsatellite stable CRC patients: ORR 30%, DCR 93%, median PFS 6.3 months.
- Left-sided tumors: 33% ORR, 100% DCR, preliminary median PFS 8.6 months.
- Rectal/rectosigmoid subgroup (n=15): 46% ORR, 100% DCR, preliminary median PFS 9.4 months.
- DKN-01 plus bevacizumab and chemotherapy well-tolerated; majority of related events Grade 1/2.
- Part B of study enrolling well, expected to complete enrollment mid-2024; conference call January 23.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1509745/000110465924004162/0001104659-24-004162-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1509745/000110465924004162/tm243430d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-004162

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer